Anti-MRSA β-lactams in development

Current Opinion in Pharmacology

Volumn 6, Issue 5, 2006, Pages 480-485

  Page, Malcolm G P ^a  

^a BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

7 [[(2 AMINO 5 CHLORO 4 THIAZOLYL)(HYDROXYIMINO)ACETYL]AMINO] 3 [[3 [[(2 AMINOETHYL)THIO]METHYL] 4 PYRIDINYL]THIO] 8 OXO 5 THIA 1 AZABICYCLO[4.2.0]OCT 2 ENE 2 CARBOXYLIC ACID; 7BETA [2 (5 AMINO 1,2,4 THIADIAZOL 3 YL) 2 ETHOXYIMINOACETAMIDO] 3 [(1 METHYLAMINOPROPYL 1H IMIDAZO[4,5 B]PYRIDINIUM 4 YL)METHYL] 3 CEPHEM 4 CARBOXYLIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CB 181963; CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE MEDOCARIL; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CS 023; IMIPENEM; LB 11058; MEROPENEM; PENICILLIN G; PPI 0903; PPI 0903M; RO 4908643; RWJ 442831; T 91825; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOCARDITIS; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OSTEOMYELITIS; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; STAPHYLOCOCCUS INFECTION; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CEPHALOSPORINS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG DESIGN; METHICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS;

EID: 33748575602     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.06.002     Document Type: Review

References (30)

1. Page M.G.P. Cephalosporins in clinical development. Expert Opin Investig Drugs 13 (2004) 973-985
2. Hebeisen P., Heinze-Krauss I., Angehrn P., Hohl P., Page M.G.P., and Then R.L. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 45 (2001) 825-836
3. Bogdanovich T., Ednie L.M., Shapiro S., and Appelbaum P.C. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 49 (2005) 4210-4219
4. Hartman B.J., and Tomasz A. Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus. J Bacteriol 158 (1984) 513-516
5. Heller S, Marrer E, Page MGP, Shapiro S, Thenoz L: Development of endogenous resistance by staphylococci to BAL9141 and comparators. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, 1-4 May 2004. Poster P675.
6. Kosowska K., Hoellman D.B., Lin G., Clark C., Credito K., McGhee P., Dewasse B., Bozdogan B., Shapiro S., and Appelbaum P.C. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob Agents Chemother 49 (2005) 1932-1942
7. Heep M, Geier C, Hofer B, Dantier C, Page MGP: Induction of ampC β-lactamases in Enterobacter cloacae triggers resistance to extended spectrum cephalosporins, but not to cefepime and ceftobiprole. 45th Interscience Congference on Qntimcrobial Agents and Chemotherapy, Washington DC, 15-19 December 2005. Poster E-308.
8. Queenan AM, Bush K: Ceftobiprole: effect on ampC β-lactamase induction and resistance frequency in Gram-negative bacteria. 45th Interscience Congference on Qntimcrobial Agents and Chemotherapy, Washington DC,15-19 December 2005. Poster C1-55.
9. Kresken M, Heep M, Wiegand I: Gram-negative bacteria producing characterised beta-lactamases: in vitro activities of BAL9141 and comparators. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, 1-4 May 2004. Poster P536.
10. Kresken M, Heep M: In vitro activities of BAL9141 and seven other beta-lactam antimicrobial agents towards clinical isolates of 12 members of the Enterobacteriaceae family. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, 1-4 May 2004. Poster P1209.
11. Kresken M, Heep M: In vitro activities of BAL9141, the active component of BAL5788, and seven other beta-lactams against selected strains of Pseudomonas aeruginosa susceptible or resistant to ceftazidime. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, 1-4 May 2004. Poster E-2022.
12. Bogdanovich T., Clark C., Ednie L., Lin G., Smith K., Shapiro S., and Appelbaum P.C. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother 50 (2006) 2050-2057
13. Vaudaux P., Gjinovci A., Bento M., Li D., Schrenzel J., and Lew D.P. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49 (2005) 3789-3793
14. Chambers H.F. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 49 (2005) 884-888
15. Yin LY, Calhoun JH, Thomas JK, Shapiro S, Schmitt-Hoffmann AH, Urwyler H: Efficacies of ceftobiprole medocaril (BDR-M), vancomycin (VAN) and linezolid (LZD) for treatment of methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis: studies with a rabbit model. 43rd Annual Meeting of the Infectious Diseases Society of America, 6-9 October 2005
16. Schmitt-Hoffmann AH, Harsch M, Heep M, Schleimer M, Brown T, Man A, O'Riordan W: BAL5788 in patients with complicated skin and skin structure infections caused by Gram-positive pathogens including methicillin-resistant Staphylococcus species. Interim pharmacokinetic results from 20 patients. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, 1-4 May 2004. Poster P1031.
17. Schmitt-Hoffmann AH, Roos B, Heep M, Schleimer M, Weidekamm E, Man A, Abdou N: Influence of gender on the pharmacokinetics of BAL9141 after intravenous infusion of pro-drug BAL5788. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, 1-4 May 2004. Poster P1030.
18. Iizawa Y., Nagai J., Ishikawa T., Hashiguchi S., Nakao M., Miyake A., and Okonogi K. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug TAK-599. J Infect Chemother 10 (2004) 146-156
19. Sader H.S., Fritsche T.R., Kaniga K., Ge Y., and Jones R.N. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob. Agents. Chemother 49 (2005) 3501-3512
20. Andes D., and Craig W.A. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK.599), active against methicillin-resistant Staphylococcus aureus in murine thigh and infection lung models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 50 (2006) 1376-1383
21. Kawamoto I., Shimoji Y., Kanno O., Kojima K., Ishikawa K., Matsuyama E., Ashida Y., Shibayama T., Fukuoka T., and Ohya S. Synthesis and structure-activity relationships of novel parenteral carbapenems. CS-023 (R-115685) and related compounds containing an amidine moiety. J Antibiot (Tokyo) 56 (2003) 565-579
22. Namba E., Inoue H., Koga T., Fukuoka T., and Simpson T. High affinity for PBP2' enables RO490-8463 (CS-023), a unique guanidine-pyrrolidine carbapenem, to achieve good in vitro activity against MRSA, which is confirmed in murine infection models. Clin Microbiol Infect 11 Suppl 2 (2005) 512
23. Koga T., Abe T., Inoue H., Takenouchi T., Kitayama A., Yoshida T., Masuda N., Sugihara C., Kakuta M., Nakagawa M., et al. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Antimicrob Agents Chemother 49 (2005) 3239-3250
24. Vouillamoz J., Entenza J.M., Hohl P., and Moreillon P. LB11058, a new cephalosporin with high penicillin-binding protein 2a affinity and activity in experimental endocarditis due to homogeneously methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 48 (2004) 4322-4327
25. Yoshizawa H., Kubota T., Itani H., Ishitobi H., Miwa H., and Nishitani Y. New broad-spectrum parenteral cephalosporins exhibiting potent activity against both methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa Part 2: synthesis and structure-activity relationships in the S - 3578 series. Bioorg Med Chem 12 (2004) 4211-4219
26. Miyazaki S., Okazaki K., Tsuji M., and Yamaguchi K. Pharmacodynamics of S - 3578 a novel cephem, in murine lung and systemic infection models. Antimicrob Agents Chemother 48 (2004) 378-383
27. Miller K., Storey C., Stubbings W.J., Hoyle A.M., Hobbs J.K., and Chopra I. Antistaphylococcal activity of the novel cephalosporin CB-181963 (CAB-175). J Antimicrob Chemother 55 (2005) 579-582
28. Fuda C., Hesek D., Lee M., Heilmeyer W., Novak R., Vakulenko S.B., and Mobashery S. Mechanistic basis for the action of new cephalosporin antibiotics effective against methicillin- and vancomycin-resistant Staphylococcus aureus. J Biol Chem 281 (2006) 10035-10041
29. Louie A, Liu W, Deziel MR, Fregeau C, Brown D, Turner L, Bush K, Drusano GL: Pharmacodynamics of a novel cephalosporin pro-drug, RWJ-442831 (RWJ), in a neutropenic mouse thigh model of MRSA infection. 44th Interscience Congference on Qntimcrobial Agents and Chemotherapy, Washington DC, 30th October-2nd November 2004. Poster A-1866.
30. Lovering A, Danel F, Page MGP, Strynadka NJ: Mechanism of action of ceftobiprole: structural basis for the anti-MRSA activity. 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, April 1-4, 2006. Poster 1586.